157 related articles for article (PubMed ID: 15801935)
1. Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects.
Astruc B; Tarral A; Dostert P; Mariotti F; Fabbri L; Imbimbo BP
Br J Clin Pharmacol; 2005 Apr; 59(4):405-14. PubMed ID: 15801935
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects.
Tarral A; Dostert P; Guillevic Y; Fabbri L; Rondelli I; Mariotti F; Imbimbo BP
J Clin Pharmacol; 2003 Aug; 43(8):901-11. PubMed ID: 12953347
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects.
Csajka C; Imbimbo BP; Piccinno A; Dostert P; Verotta D
J Pharmacol Exp Ther; 2005 May; 313(2):647-57. PubMed ID: 15671203
[TBL] [Abstract][Full Text] [Related]
4. CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model.
Mathiesen O; Imbimbo BP; Hilsted KL; Fabbri L; Dahl JB
J Pain; 2006 Aug; 7(8):565-74. PubMed ID: 16885013
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
7. CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats.
Bassani F; Bergamaschi M; Tonino Bolzoni P; Villetti G
Eur J Pharmacol; 2005 Sep; 519(3):231-6. PubMed ID: 16125167
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
Marzo A; Dal Bo L; Monti NC; Crivelli F; Ismaili S; Caccia C; Cattaneo C; Fariello RG
Pharmacol Res; 2004 Jul; 50(1):77-85. PubMed ID: 15082032
[TBL] [Abstract][Full Text] [Related]
9. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
10. The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.
van der Post JP; de Visser SJ; de Kam ML; Woelfler M; Hilt DC; Vornov J; Burak ES; Bortey E; Slusher BS; Limsakun T; Cohen AF; van Gerven JM
Br J Clin Pharmacol; 2005 Aug; 60(2):128-36. PubMed ID: 16042665
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration.
Farré M; Roset PN; Llorente M; Márquez M; Albet C; Pérez JA; Herrero E; Ortíz JA
Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):343-50. PubMed ID: 9379783
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of action of CHF3381 in the forebrain.
Barbieri M; Bregola G; Buzzi A; Marino S; Zucchini S; Stables JP; Bergamaschi M; Pietra C; Villetti G; Simonato M
Br J Pharmacol; 2003 Aug; 139(7):1333-41. PubMed ID: 12890713
[TBL] [Abstract][Full Text] [Related]
13. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
15. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
Cilla DD; Whitfield LR; Gibson DM; Sedman AJ; Posvar EL
Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration.
Tiseo PJ; Rogers SL; Friedhoff LT
Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):13-8. PubMed ID: 9839760
[TBL] [Abstract][Full Text] [Related]
17. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects.
Dingemanse J; Wood N; Jorga K; Kettler R
Br J Clin Pharmacol; 1997 Jan; 43(1):41-7. PubMed ID: 9056051
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I study.
Sádaba B; Azanza JR; Quetglas EG; Campanero MA; Honorato J; Coronel P; Gimeno M
Rev Esp Quimioter; 2007 Mar; 20(1):51-60. PubMed ID: 17530036
[TBL] [Abstract][Full Text] [Related]
20. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.
Kubitza D; Becka M; Wensing G; Voith B; Zuehlsdorf M
Eur J Clin Pharmacol; 2005 Dec; 61(12):873-80. PubMed ID: 16328318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
